Literature DB >> 31840746

Liver Fibrosis Progression and Mortality in Hepatitis B- and C-Coinfected Persons Treated With Directly Acting Antiviral Agents: Results From ERCHIVES.

Adeel A Butt1,2,3, Peng Yan1, Samia Aslam1, Abdul-Badi Abou-Samra2,3, Kenneth E Sherman4, Obaid S Shaikh1.   

Abstract

For persons with baseline Fibrosis-4 1.46-3.25, cirrhosis incidence/1000 patient-years was 49.3 among hepatitis B virus (HBV)/hepatitis C virus (HCV) coinfected and 18.2 among HCV monoinfected (P = .03). Cirrhosis risk was numerically higher but statistically nonsignificant among HBV/HCV coinfected (hazards ratio [HR] 1.51; 95% confidence intervals [CI], .37-6.05) but lower among those who attained sustained virologic response (HR, .52; 95% CI, .42-.63).
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  ERCHIVES; HBV; HCV; HCV/HBV coinfection; fibrosis progression

Year:  2020        PMID： 31840746      PMCID： PMC7530468          DOI： 10.1093/cid/ciz1097

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  12 in total

1.  Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents.

Authors:  Vincenza Calvaruso; Giuseppe Cabibbo; Irene Cacciola; Salvatore Petta; Salvatore Madonia; Alessandro Bellia; Fabio Tinè; Marco Distefano; Anna Licata; Lydia Giannitrapani; Tullio Prestileo; Giovanni Mazzola; Maria Antonietta Di Rosolini; Licia Larocca; Gaetano Bertino; Antonio Digiacomo; Francesco Benanti; Luigi Guarneri; Alfonso Averna; Carmelo Iacobello; Antonio Magro; Ignazio Scalisi; Fabio Cartabellotta; Francesca Savalli; Marco Barbara; Antonio Davì; Maurizio Russello; Gaetano Scifo; Giovanni Squadrito; Calogero Cammà; Giovanni Raimondo; Antonio Craxì; Vito Di Marco
Journal:  Gastroenterology       Date:  2018-04-12       Impact factor: 22.682

2.  Performance of the Pooled Cohort atherosclerotic cardiovascular disease risk score in hepatitis C virus-infected persons.

Authors:  K W Chew; D Bhattacharya; T B Horwich; P Yan; K A McGinnis; C Tseng; M S Freiberg; J S Currier; A A Butt
Journal:  J Viral Hepat       Date:  2017-04-10       Impact factor: 3.728

3.  Hepatitis C Virus (HCV) Treatment With Directly Acting Agents Reduces the Risk of Incident Diabetes: Results From Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES).

Authors:  Adeel A Butt; Peng Yan; Samia Aslam; Obaid S Shaikh; Abdul-Badi Abou-Samra
Journal:  Clin Infect Dis       Date:  2020-03-03       Impact factor: 9.079

4.  HCV treatment initiation in persons with chronic kidney disease in the directly acting antiviral agents era: Results from ERCHIVES.

Authors:  Adeel A Butt; Yanjie Ren; Amy Puenpatom; Jean-Marie Arduino; Ritesh Kumar; Abdul-Badi Abou-Samra
Journal:  Liver Int       Date:  2018-01-19       Impact factor: 5.828

5.  The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: An ERCHIVES study.

Authors:  Darrick K Li; Yanjie Ren; Daniel S Fierer; Stephanie Rutledge; Obaid S Shaikh; Vincent Lo Re; Tracey Simon; Abdul-Badi Abou-Samra; Raymond T Chung; Adeel A Butt
Journal:  Hepatology       Date:  2018-04-19       Impact factor: 17.425

6.  Validity of diagnostic codes and liver-related laboratory abnormalities to identify hepatic decompensation events in the Veterans Aging Cohort Study.

Authors:  Vincent Lo Re; Joseph K Lim; Matthew Bidwell Goetz; Janet Tate; Harini Bathulapalli; Marina B Klein; David Rimland; Maria C Rodriguez-Barradas; Adeel A Butt; Cynthia L Gibert; Sheldon T Brown; Farah Kidwai; Cynthia Brandt; Zachariah Dorey-Stein; K Rajender Reddy; Amy C Justice
Journal:  Pharmacoepidemiol Drug Saf       Date:  2011-05-27       Impact factor: 2.890

7.  Profile and value of FIB-4 in patients with dual chronic hepatitis C and B.

Authors:  Chun-Jen Liu; Tai-Chung Tseng; Wan-Ting Yang; Tung-Hung Su; Hung-Chih Yang; Chen-Hua Liu; Pei-Jer Chen; Ding-Shinn Chen; Jia-Horng Kao
Journal:  J Gastroenterol Hepatol       Date:  2018-09-20       Impact factor: 4.029

8.  The negative impact of HBV/HCV coinfection on cirrhosis and its consequences.

Authors:  S Pol; G Haour; H Fontaine; C Dorival; V Petrov-Sanchez; M Bourliere; J Capeau; P Carrieri; D Larrey; C Larsen; P Marcellin; J-M Pawlostky; P Nahon; F Zoulim; P Cacoub; V de Ledinghen; P Mathurin; F Negro; G-P Pageaux; Y Yazdanpanah; L Wittkop; J-P Zarski; F Carrat
Journal:  Aliment Pharmacol Ther       Date:  2017-10-09       Impact factor: 8.171

9.  Epidemiology and clinical outcomes of hepatitis delta (D) virus infection in Queensland, Australia.

Authors:  Sarah Coghill; John McNamara; Marion Woods; Krispin Hajkowicz
Journal:  Int J Infect Dis       Date:  2018-07-09       Impact factor: 3.623

10.  Effect of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir and Ledipasvir/Sofosbuvir Regimens on Survival Compared With Untreated Hepatitis C Virus-Infected Persons: Results From ERCHIVES.

Authors:  Adeel Ajwad Butt; Peng Yan; Tracey G Simon; Abdul-Badi Abou-Samra
Journal:  Clin Infect Dis       Date:  2017-09-15       Impact factor: 9.079
View more
  1 in total

Review 1.  Hepatitis C Virus and Hepatitis B Virus Co-Infection.

Authors:  Yi-Fen Shih; Chun-Jen Liu
Journal:  Viruses       Date:  2020-07-10       Impact factor: 5.048
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.